From: A systematic review of community based hepatitis C treatment
Study | Study population and policy for initiating treatment (if included in publication) | Facility | N | OST (%) | Active illicit substance use | Treatment uptake |
---|---|---|---|---|---|---|
n (%) | ||||||
Bruce | HCV infection +/− HIV Attendance at OST clinic Rx according to published guidelines and the same in both facilities | Tertiary | 9 | 100 | Opioid negative on urine toxicology in past 30 days | 4 (44) |
Primary | 12 | 100 | Opioid negative on urine toxicology in past 30 days | 12 (100) | ||
Gigi | HCV antibody positive Attended Liver clinic or OST clinic Policy for Rx initiation not published | Tertiary | 643 | 0 | Nil | 276 (43) |
Primary | 204 | 100 | Nil | 17 (8) | ||
Kramer | HCV infection Designated Primary Care Provider Majority of care from one Veterans Affairs facility Rx indicated if more than portal fibrosis and no contraindications (including no active illicit drug use) | Specialist clinic | 24,853 | N/P | N/P | 3537 (14) |
Primary clinic | 1929 | N/P | N/P | 251 (13) | ||
Kuo | HCV antibody positive Participation in screening program Pre-intervention Rx if: ALT >40 (once) and > F1 or HCV RNA positive Post intervention Rx if ALT >80 (twice) and > F1 | Pre intervention | 18 | N/P | N/P | 4 (22) |
Post intervention | N/P | N/P | 3 (19) | |||
Moriarty | HCV infection Attendance at outreach clinic Policy for Rx initiation not published | Tertiary | 51 | N/P | N/P | 1 (2) |
Primary | N/P | N/P | 4 (8) | |||
Moussalli | HCV infection Attendance at OST Primary healthcare facility Rx if > F2 fibrosis | Pre-intervention | 337 | N/P | N/P | 2 (0.6) |
Post intervention | N/P | N/P | 85 (25) |